Brought to you by 
Series E round brings $85.4mm to Sutro Biopharma
15 Nov 2018
Executive Summary
Sutro Biopharma Inc. (oncology) raised $85.4mm through its Series E round. Samsara BioCapital and Surveyor Capital co-led and were joined by existing backers Alta Partners, Amgen Ventures, Celgene, Lilly Ventures, Skyline Ventures, and SV Health Investors, as well as new investors Eventide, Nexthera Capital, Vida Ventures, and funds managed by Tekla Capital Management.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series E round brings $85.4mm to Sutro Biopharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice